NCT07683104
Natural History of Trisomy 8-Associated Autoinflammatory Disease (TRIAD) and Related Disorders
StatusRecruiting
PhaseNot specified
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
The 50 most recent of 84 versions: 50 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Start date changed from estimate of Nov 18, 2026 to Nov 10, 2026
- Minor Start date: Nov 17, 2026 to Nov 18, 2026
- Minor Start date: Nov 15, 2026 to Nov 17, 2026
- Minor Start date: Nov 12, 2026 to Nov 15, 2026
- Minor Start date: Nov 11, 2026 to Nov 12, 2026
Show 45 earlier versionsHide 45 earlier versions
- Minor Start date: Nov 10, 2026 to Nov 11, 2026
- Minor Start date: Nov 9, 2026 to Nov 10, 2026
- Minor Start date: Nov 8, 2026 to Nov 9, 2026
- Minor Start date: Nov 5, 2026 to Nov 8, 2026
- Minor Start date: Nov 4, 2026 to Nov 5, 2026
- Minor Start date: Nov 3, 2026 to Nov 4, 2026
- Minor Start date: Nov 2, 2026 to Nov 3, 2026
- Minor Start date: Nov 1, 2026 to Nov 2, 2026
- Minor Start date: Oct 29, 2026 to Nov 1, 2026
- Minor Start date: Oct 28, 2026 to Oct 29, 2026
- Minor Start date: Oct 27, 2026 to Oct 28, 2026
- Minor Start date: Oct 26, 2026 to Oct 27, 2026
- Minor Start date: Oct 25, 2026 to Oct 26, 2026
- Minor Start date: Oct 22, 2026 to Oct 25, 2026
- Minor Start date: Oct 21, 2026 to Oct 22, 2026
- Minor Start date: Oct 20, 2026 to Oct 21, 2026
- Minor Start date: Oct 19, 2026 to Oct 20, 2026
- Minor Start date: Oct 18, 2026 to Oct 19, 2026
- Minor Start date: Oct 14, 2026 to Oct 18, 2026
- Minor Start date: Oct 13, 2026 to Oct 14, 2026
- Minor Start date: Oct 12, 2026 to Oct 13, 2026
- Minor Start date: Oct 11, 2026 to Oct 12, 2026
- Minor Start date: Oct 8, 2026 to Oct 11, 2026
- Minor Start date: Oct 7, 2026 to Oct 8, 2026
- Minor Start date: Oct 6, 2026 to Oct 7, 2026
- Minor Start date: Oct 5, 2026 to Oct 6, 2026
- Minor Start date: Oct 4, 2026 to Oct 5, 2026
- Minor Start date: Sep 20, 2026 to Oct 4, 2026
- Minor Start date: Sep 17, 2026 to Sep 20, 2026v51
- Minor Start date: Sep 16, 2026 to Sep 17, 2026v50
- Minor Start date: Sep 15, 2026 to Sep 16, 2026v49
- Minor Start date: Sep 14, 2026 to Sep 15, 2026v48
- Minor Start date: Sep 10, 2026 to Sep 14, 2026v47
- Minor Start date: Sep 9, 2026 to Sep 10, 2026v46
- Minor Start date: Sep 8, 2026 to Sep 9, 2026v45
- Minor Start date: Sep 7, 2026 to Sep 8, 2026v44
- Minor Start date: Sep 6, 2026 to Sep 7, 2026v43
- Minor Start date: Sep 3, 2026 to Sep 6, 2026v42
- Minor Start date: Sep 2, 2026 to Sep 3, 2026v41
- Minor Start date: Sep 1, 2026 to Sep 2, 2026v40
- Minor Start date: Aug 31, 2026 to Sep 1, 2026v39
- Minor Start date: Aug 30, 2026 to Aug 31, 2026v38
- Minor Start date: Aug 27, 2026 to Aug 30, 2026v37
- Minor Start date: Aug 26, 2026 to Aug 27, 2026v36
- Minor Start date: Aug 25, 2026 to Aug 26, 2026v35
- Minor: routine updates
Endpoints
Primary
Clinical characterization of participants with trisomy 8 mosaicism and related disorders based on history, physical examination, radiologic imaging, and laboratory testing.
Timeframe: Length of the study
Characterization of immunologic profile of participants with trisomy 8 mosaicism and related disorders over time in comparison to healthy controls using cellular and molecular techniques
Timeframe: Length of the study
Secondary (4)
Characterization of laboratory, radiologic examinations, biopsies, and physical exam findings.
Identification of individuals with trisomy 8 who develop malignancy and assessment of risk factors including but not limited to history, findings on bone marrow biopsies and CBCs, NGS for risk variants, and flow cytometry.
Determination of the percentage of trisomy 8 cells in various tissue types including bone marrow, blood, fibroblasts cultured from skin, and biopsy samples, and the association with clinical phenotype.
Assessment of treatment response based on inflammatory markers, clinical history, and physical exam findings.
Arms and interventions
Affected Participants
Individuals ages \<= 99 with known or suspected trisomy 8 mosaicism, or with clinical phenotype consisting of mucosal ulcerations similar to TRIAD.
Non-affected biological family member participants
Non-affected biological family members of enrolled participants.
Sites
1 site in 1 country
- National Institutes of Health Clinical CenterBethesda, Maryland, United States